|
|
|
|
|
Naratriptan
drug data and news
Naratriptan drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Naratriptan | ||
| Brand Names/Synonyms | Amerge; CHEMBANK1626; Naratriptan | ||
| Indication | For the acute treatment of migraine attacks with or without aura in adults. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Naratriptan is a selective 5-hydroxytryptamine receptor subtype agonist indicated for the acute treatment of migraine attacks with or without aura in adults. Naratriptan is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. Naratriptan is an agonist for a vascular 5-hydroxytryptamine receptor subtype (probably a member of the 5-HT1D family) having only a weak affinity for significant affinity or pharmacological activity at 5-HT2, or beta-adrenergic, dopamine1,; dopamine2; muscarinic, or benzodiazepine receptors. This action in humans correlates with the relief of migraine headache. In addition to causing vasoconstriction, experimental data from animal studies show that Naratriptan also activates 5-HT1 receptors on peripheral terminals of the trigeminal nerve innervating cranial blood vessels, which may also contribute to the antimigrainous effect of Naratriptan in humans. | ||
| Mechanism Of Action | Naratriptan binds with high affinity to human 5-HT1B and | ||
| Naratriptan News (When available) |
Allergan Enters Into Agreement with GlaxoSmithKline to Accelerate ... Oct 3, 2005 E-prescribing System Had No Effect on Formulary Compliance or ... Jun 6, 2005 Used to treat: Severe migraine attacks Apr 24, 2005 /FIRST ADD -- NYTU041B -- Pfizer Inc Earnings/ Apr 19, 2005 Triptan Nonresponder Studies: Implications for Clinical Practice Mar 7, 2005 | ||
| Dosage Forms | TABLET | ||
| Drug_Category | Vasoconstrictor Agents; Selective Serotonin Agonists; ATC:N02CC02 | ||
| Absorption | Well absorbed (74% oral biovaility), absorption is rapid with peak plasma concentrations after 2-5 hours | ||
| Interactions |
-->Interactions for Naratriptan: Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated. The administration of naratriptan with other 5-HT1 agonists has not been evaluated in migraine patients. Because their vasospastic effects may be additive, coadministration of naratriptan and other 5-HT1 agonists within 24 hours of each other is not recommended. Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HTv agonists. If concomitant treatment with naratriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.Drug/ Laboratory Test Interactions AMERGE Tablets are not known to interfere with commonly employed clinical laboratory tests. | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | N-methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]-ethanesulfonamide | ||
| Chemical Formula | C17H25N3O2S | ||
| Molecular Weight | 335.465 g/mol | ||
| Smiles String | CNS(=O)(=O)CCC1=CC2=C(C=C1)NC=C2C3CCN(CC3)C | ||
| Melting Point | 246 oC (HCl salt) | ||
| Water Solubility | 35 mg/mL | ||
| State | Solid | ||
| LogP/Hphobicity | 1.812 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Primarily hepatic | ||
| Half Life | 5-8 hours | ||
| Protein Binding [%] | 28%-31% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Naratriptan.html http://www.rxlist.com/cgi/generic2/naratript.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00220 | ||
| CAS Registry Number | 121679-13-8 | ||
| KEGG Compound ID | C07792 | ||
| PubChem ID | SID:65618 | ||
| PharmGKB ID | PA450597 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2237821 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |